ArticleJournal of neuro-oncology2026
Incidence of intra-axial brain metastases in Eastern Finland.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBrain metastases (BM) incidence and characteristics remain poorly defined due to registry data being often incomplete, recording only primary tumors or unspecified metastases. The objective of this study was to examine BM incidence rates and characteristics confirmed by MRI in North Savo, Finland.
methodsIn this retrospective study, North Savo residents with first MRI diagnosis of BM between 1 January 2004 and 31 December 2023 were identified through the radiology information system, irrespective of primary cancer diagnosis date. Medical and histopathological records were reviewed. Population person-years were estimated by summing annual end-year counts of all North Savo residents obtained from Statistics Finland. Crude incidence rates and age-standardized incidence rates (ASIRs), standardized to the 2013 European Standard population, were calculated. Temporal trends were assessed using age-adjusted Poisson regression.
resultsAmong 516 patients, 474 had histopathological verification. Cancers originating from lung and breast tissue accounted for 56.8% of BM cases. Overall crude incidence was 10.22 (95% CI 9.36-11.15) and ASIR was 9.20 (95% CI 8.42-10.04) per 100,000 person years. ASIR increased from 5.8 in 2004-2008 to 11.8 in 2019-2023. Age-adjusted Poisson regression estimated a 24% increase in incidence per five-year period (incidence rate ratio 1.24; 95% CI 1.14-1.34; P < 0.001). Age-specific incidence peaked at 33.1 per 100,000 person years among patients aged 70-74 years.
conclusionsMRI-confirmed BM incidence increased over 20 years, despite age standardization. Incidence was highest among older adults. These findings provide contemporary population-based epidemiological data of BM incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.